机构：[a]Department of Pain Management, Xuanwu Hospital of Capital Medical University, Beijing, China.疼痛科首都医科大学宣武医院[b]Central Laboratory, Xuanwu Hospital of Capital Medical University, Beijing, China.首都医科大学宣武医院[c]Liver Cancer Center, The 302 Hospital, Beijing, China.[d]Department of Radiology, Xuanwu Hospital of Capital Medical University, Beijing, China.放射科首都医科大学宣武医院
Rationale: Pain is one of the most common and distressing symptoms experienced by cancer patients. Cancer pain is a complex phenomenon with physical, psychological, social, and cognitive domains. Although opioids remain a cornerstone of cancer pain management, they are not effective in all patients. This case highlights the successful treatment of an opioid-refractory severe cancer pain crisis with ropivacaine infusion and subsequent rapid tapering of opioid dose. Patient concerns: This report illustrates the use of ropivacaine for cancer pain. A 62-year-old man with metastatic lung cancer was admitted to the hospital with uncontrolled chest-back and abdominal pain. Diagnoses: The patient was diagnosed as refractory cancer pain. Interventions: Successful treatment with morphine and ropivacaine was performed to obtain longer opioid refractory severe cancer pain. Outcomes: At 1, 3, and 6 months postoperative review, 70-75% relief of pain was achieved with overall activity was improved. The analgesic effect was stable during the 6-month follow-up period. No complications were reported during the follow-up period. Lessons: Our report demonstrates that ropivacaine is successful treatment for cancer pain in this case. It will supply us a novel navigation in cancer pain treatments. Meanwhile, this finding still needs additional study for confirmation.
基金：
National Natural Science Foundation of China (No. 81502553);
Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (No. ZYLX201507);
Capital Characteristic Clinic Project (No. Z141107002514065);
National Natural Science Foundation of China (No. 81271556);
National Natural Science Foundation of China (No. 81672467);
National Natural Science Foundation of China (No.81470165);
the Natural Science Foundation of Beijing (No. 7172207).
第一作者机构：[a]Department of Pain Management, Xuanwu Hospital of Capital Medical University, Beijing, China.[b]Central Laboratory, Xuanwu Hospital of Capital Medical University, Beijing, China.[c]Liver Cancer Center, The 302 Hospital, Beijing, China.
通讯作者：
通讯机构：[a]Department of Pain Management, Xuanwu Hospital of Capital Medical University, Beijing, China.[b]Central Laboratory, Xuanwu Hospital of Capital Medical University, Beijing, China.[c]Liver Cancer Center, The 302 Hospital, Beijing, China.
推荐引用方式(GB/T 7714)：
Hongyan Li ,Liqiang Yang ,Zhaoxuan Guo,et al.Successful treatment of refractory cancer pain with morphine and ropivacaine A case report[J].MEDICINE.2017,96(22):e7052.doi:10.1097/MD.0000000000007052.
APA：
Hongyan Li,,Liqiang Yang,,Zhaoxuan Guo,Yuanzhang Tang,,Nan Chen,...&Jiaxiang Ni.(2017).Successful treatment of refractory cancer pain with morphine and ropivacaine A case report.MEDICINE,96,(22)
MLA：
Hongyan Li,,et al."Successful treatment of refractory cancer pain with morphine and ropivacaine A case report".MEDICINE 96..22(2017):e7052
